PDF(Pubmed)
Abstract：
Iron deficiency (ID) and iron-deficiency anaemia (IDA) are global public health concerns, most commonly afflicting children, pregnant women and women of childbearing age. Pathological outcomes of ID include delayed cognitive development in children, adverse pregnancy outcomes and decreased work capacity in adults. IDA is usually treated by oral iron supplementation, typically using iron salts (e.g. FeSO4 ); however, dosing at several-fold above the RDA may be required due to less efficient absorption. Excess enteral iron causes adverse gastrointestinal side effects, thus reducing compliance, and negatively impacts the gut microbiome. Recent research has sought to identify new iron formulations with better absorption so that lower effective dosing can be utilized. This article outlines emerging research on oral iron supplementation and focuses on molecular mechanisms by which different supplemental forms of iron are transported across the intestinal epithelium and whether these transport pathways are subject to regulation by the iron-regulatory hormone hepcidin.
摘要：
缺铁（ID）和缺铁性贫血（IDA）是全球公共卫生问题，最常见的折磨儿童，孕妇和育龄妇女。ID的病理结果包括儿童认知发育迟缓，不良妊娠结局和成人工作能力下降。IDA通常通过口服铁补充剂来治疗，通常使用铁盐（例如FeSO4）；然而，由于吸收效率较低，可能需要在RDA以上几倍的剂量。过量的肠内铁会导致不良的胃肠道副作用，从而降低了合规性，并对肠道微生物组产生负面影响。最近的研究试图确定具有更好吸收的新的铁制剂,从而可以利用较低的有效剂量。本文概述了口服铁补充剂的新兴研究，并着重于不同补充形式的铁通过肠上皮转运的分子机制，以及这些转运途径是否受到铁调节激素hepcidin的调节。
